Health Canada and European Medicines Agency have decided to reintroduce the use of aprotinin after its withdrawal from the worldwide market in 2007. However, this puts the cardiac surgery patients at risk.The authors of a previous major trial that found a substantially increased risk of death associated with the drug. In an analysis in emCMAJ (Canadian Medical Association Journal/em), the authors refute three major criticisms of the trial made by the regulatory bodies. ...
Read MoreYou have just read an article categorized health
titled Reintroducing Aprotinin in Cardiac Surgery is Risky for Patients.
Written by:
editor - Tuesday, September 30, 2014
There are currently no comments for "Reintroducing Aprotinin in Cardiac Surgery is Risky for Patients"
Post a Comment